Royal Bank of Canada Reiterates “Outperform” Rating for 4basebio (LON:4BB)

Royal Bank of Canada restated their outperform rating on shares of 4basebio (LON:4BB) in a research report released on Thursday, Marketbeat Ratings reports. The firm currently has a GBX 1,600 ($20.70) price target on the stock.

4basebio Stock Performance

Shares of 4BB opened at GBX 1,132 ($14.64) on Thursday. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm’s fifty day simple moving average is GBX 1,167.33 and its two-hundred day simple moving average is GBX 1,263.27. 4basebio has a 12 month low of GBX 901 ($11.65) and a 12 month high of GBX 1,820 ($23.54). The stock has a market capitalization of £145.01 million, a P/E ratio of -1,451.28 and a beta of 1.09.

Insider Activity at 4basebio

In related news, insider Amy Walker bought 1,151 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average cost of GBX 1,120 ($14.49) per share, with a total value of £12,891.20 ($16,674.69). 68.44% of the stock is owned by corporate insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.